Ocular therapeutics company Novaliq said today that it inked a strategic licensing agreement with AFT Pharmaceuticals for the commercialization of its dry eye therapy, NovaTears, in Australia and New Zealand.
NovaTears is the Germany-based company’s 1st commercially available product indicated for the treatment of evaporative dry eye diseases.
Get the full story at our sister site, Drug Delivery Business News.